acecainide nacetylprocainamide napa antiarrhythmic drug chemically nacetylated metabolite procainamide class iii antiarrhythmic agent whereas procainamide class ia antiarrhythmic drug partially active procainamide checking levels must included final calculation early claude beck undertaking pioneer cardiac surgery lakeside hospital cleveland ohio surgery facing problems arrhythmias problems investigated frederick r mautz experiments used drugs similar cocaine drugs readily absorbed mucous membranes also known effect myocardium mautz tried procaine action shortlived owing digestion esterases procaine mautz synthesized procainamide substrate esterases procainamide additional advantage active mouth procainamide approved us fda june brand name pronestyl pronestyl launched bristolmyers squibb pharmaceutical company us along discovery procainamide came discovery metabolite procainamide metabolized liver acecainide nacetyltransferase enzyme genetically nacetyltransferase enzyme catalyzes transfer acetyl groups acetylcoa arylamines aromatic amines reaction known acetylation reaction refers process introducing acetyl group resulting acetoxy group compound namely substitution acetyl group active hydrogen atom acecainide major metabolite antiarrhythmic drug procainamide measurements procainamide serum may accurately reflect drugs complete pharmacologic activity body monitoring acecainide levels along procainamide recommended procainamide therapy acecainide considered comparable activity parent compound however acecainide levels vary widely serum levels acecainide increase patients chronic procainamide therapy particularly renal impairment average serum concentration ratio acecainide procainamide depending genetically determined tendency acetylate procainamide rapidly slowly ratio varies patient patient measuring serum acecainide procainamide together helps achieve optimum antiarrhythmic effect reduce risk acecainide potassiumchannel blocker like class iii antiarrhythmic compounds compounds bind potassium channels delays phase repolarization electrophysiological changes decrease sensitiveness cells electrical stimuli leads increase action potential duration increase effective refractory period increasing effective refractory period napa useful suppressing tachyarrhythmias caused reentry ventricular way napa increase q interval pqrst heart acecainide pharmacologically active antiarrhythmic agent electrophysiological effects class iii antiarrhythmic drug used medicine increase q interval pqrst heart rhythm patients cardiac arrhythmias equivalent drug procainamide class ia antiarrhythmic drug also used patients cardiac nevertheless napa affect q interval procainamide also effect also electrophysiologic properties napa little bit different procainamide napa completely effective suppressing ventricular dysrhythmias antiarrhythmic mechanisms similar pharmacokinetic properties acecainide active metabolite procainamide studied healthy people patients cardiomyopathy elderly younger patients healthy people mean peak plasma concentrations following oral doses mg napa mgl attained hours administration patients cardiomyopathy mean peak plasma concentration mgl hours ingestion acecainide bioavailability mean peak plasma occurring mean apparent volume distribution range lkg healthy people patients cardiomyopathy steady state volume distribution lkg healthy subjects lkg patients coronary artery disease lkg patients ventricular arrhythmias receiving acecainide acecainide volume distribution lkg less vd procainamide lkg also binds less proteins procainamide low volume distribution concluded medicine thought confined plasma liquid parts body acecainide metabolised several products acecainide convert procainamide deacetylation clearance acecainide lh compare total napa clearance lh indicating napa converted procainamide desethylated convert unidentified metabolites excreted unchanged following oral administration dose acecainide excreted unchanged renal clearance acecainide following short long term administration ranges mlminkg mlminkg healthy people linear relationship acecainide clearance creatinine however clearance acecainide reduced patients cardiomyopathyand ventricular arrhythmias also excretion procainamide napa reduced patients major reaction procainamide several drugs syndrome closely resembles lupus reactive metabolite possibly nitrosoprocainamide thought play role lupus reaction acecainide unlike procainamide appears form reactive metabolite mean plasma elimination halflives healthy subjects range hours following single repeated doses sampling times hours used tendency prolongation halflives noted patients cardiomyopathy patients steadystate procainamide acecainide concentrations used compute procainamide clearance acecainideprocainamide napapa concentration ratio using stepwise multiple linear regression age creatinine clearance congestive heart failure found influence procainamide clearance significantly p less age creatinine clearance effected napapa concentration ratio p less based data age appears independent effect procainamide clearance napapa ratio separate decline renal function occurs elderly given either intravenously orally eliminated primarily renal excretion comparative studies antiarrhythmic drugs undertaken apart small study atrial flutter napa better quinidine plus digoxin although clinical experience required relative place acecainide therapy determined drug nevertheless appears offer advantages procainamide particularly respect reduced formation antinuclear antibodies dose acecainide adjusted control patients arrhythmias regard clinical state including age renal function concurrent administration drugs appears overlap plasma concentrations required therapeutic efficacy associated adverse effects rapid bolus infusion acecainide associated serious hypotension maximum infusion rate mgmin intravenous infusion mgkgmin minutes followed mgmlmin minutes maintenance infusion suppressed pvcs doses acecainide mgkg also effective preventing induced ventricular tachycardia prolonging ventricular tachycardia cycle length reducing frequency pvcs however dosage required maintain antiarrhythmic effects still shortterm prolonged studies acecainide g single dose three four divided doses day appears satisfactory controlling pvcs patients refractory antiarrhythmic agents doses required appear greater moreover studies inferred tolerance may develop longterm administration napa necessitating increased doses specific dosage recommendations patients left ventricular dysfunction although care taken reduce dose patients moderate severe renal loading dose medicine mgkg administered minutes people without insufficient renal function decreased cardiac output mgkg people disorders also described formula loading dose ld vsslkg ibwkg cpmgl x f daily empiric oral dose calculated next formula daily dose cssave cl x f decreased patients heart andor liver failures decreased patients renal research shows accumulation acecainide procainamide therapy alter procainamide elimination well electrophysiologic healthy people demonstrated concomitantly administered trimethoprim decreased renal clearance procainamide formed napa resulting increased plasma concentrations drugs increases qtc procainamide trimethoprim procainamide acecainide excreted active tubular secretion also amiodarone cimetidine trimethoprim increase napa serum level cimetidine ranitidine possibly increase plasma procainamide napa concentrations subsequent furthermore alcohol enhances acetylation procainamide napa alcohol consumption may reduce also shown coadministration paraaminobenzoic acid decreases biotransformation procainamide acecainide patient rapid acetylation measuring ratio acecainide procainamide concentrations together helps achieve optimum antiarrhythmic effect reduce risk acecainide cause cardiac toxicity effects torsades de pointes also acecainide decrease renal function accumulated procainamide therapy furthermore acecainide lead low blood pressure serious left ventricle depression present toxic common side effects napa gastrointestinal disturbances insomnia dizziness lightheadedness blurred vision numbness tingling large resemblance reported concentration range associated arrhythmic suppression acecainide range concentrations intolerable side effects begin develop severe cardiac toxicity notified oral intake despite plasma concentrations high microgramsml however hypotension reported association rapid injection animals acecainide positive inotropic effects also causes negative chronotropic hypotensive cardiovascular pharmacodynamics procainamide napa well identified small rodents without presence anesthesia restraint researchers trying make models effects procainamide acecainide abt nonselective inhibitor cytochrome enzymes recent research confirmed inhibitor also inhibit nacetylation procainamide rats oral abt decreases clearance intravenous procainamide followed decreased acecainidetoprocainamide ratio urine plasma studies humans also shows abt inhibitor nacetyltransfersase studies claim abt potent inhibitor nacetyltransferase compared nacetyltransferase httpsenwikipediaorgwikiacecainide